{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:38:02Z","timestamp":1787319482763,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,20]]},"DOI":"10.7759\/cureus.69791","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T08:01:33Z","timestamp":1726819293000},"source":"Crossref","is-referenced-by-count":3,"title":["Correlation Between the Prevalence of Myasthenia Gravis and the Frequency of Class II Human Leucocyte Antigen Alleles in Various Geographical Locations Around the World"],"prefix":"10.7759","author":[{"given":"Mathew","family":"Kurian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/138920207783591690","article-title":"The HLA region and autoimmune disease: associations and mechanisms of action","volume":"8","author":"Gough SC","year":"2007","unstructured":"Gough SC, Simmonds MJ. The HLA region and autoimmune disease: associations and mechanisms of action. Curr Genomics. 2007, 8:453-65. 10.2174\/138920207783591690","journal-title":"Curr Genomics"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-1578(10)60658-7","article-title":"Human leukocyte antigen gene polymorphism and the histocompatibility laboratory","volume":"3","author":"Williams TM","year":"2001","unstructured":"Williams TM. Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. J Mol Diagn. 2001, 3:98-104. 10.1016\/S1525-1578(10)60658-7","journal-title":"J Mol Diagn"},{"key":"ref3","unstructured":"Genetics Home Reference. Human leukocyte antigens. Accessed. 11\/01\/2018: https:\/\/medlineplus.gov\/genetics\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.169367","article-title":"Myasthenia and related disorders of the neuromuscular junction","volume":"81","author":"Spillane J","year":"2010","unstructured":"Spillane J, Beeson DJ, Kullmann DM. Myasthenia and related disorders of the neuromuscular junction. J Neurol Neurosurg Psychiatry. 2010, 81:850-7. 10.1136\/jnnp.2008.169367","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12173","article-title":"Characteristics of myasthenia gravis with antibodies to muscle\u2010specific kinase and low\u2010density lipoprotein\u2010related receptor protein 4","volume":"6","author":"Evoli A","year":"2015","unstructured":"Evoli A, Iorio R. Characteristics of myasthenia gravis with antibodies to muscle\u2010specific kinase and low\u2010density lipoprotein\u2010related receptor protein 4. Clinical and Experimental Neuroimmunology. 2015, 6:40-8. 10.1111\/cen3.12173","journal-title":"Clinical and Experimental Neuroimmunology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc AM","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021, 14:7-16. 10.25122\/jml-2020-0145","journal-title":"J Med Life"},{"key":"ref7","unstructured":"Myasthenia Gravis Foundation of America. Clinical overview. https.\/\/myasthenia.org\/Understanding-MG\/Overview-of-MG#:~:text=Myasthenia%20gravis%20(pronounced%20%60my%CB%96,signal...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015, 14:1023-36. 10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/874680","article-title":"Myasthenia gravis: a review","volume":"2012","author":"Jayam Trouth A","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012, 2012:874680. 10.1155\/2012\/874680","journal-title":"Autoimmune Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel VC","year":"2007","unstructured":"Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007, 2:44. 10.1186\/1750-1172-2-44","journal-title":"Orphanet J Rare Dis"},{"key":"ref11","unstructured":"Myasthenia Gravis Foundation of America. Treatment for MG. Accessed. 02\/02\/2018: https:\/\/myasthenia.org\/Treatments\/Treatment-Overview#:~:text=While%20there%20is%20no%20known,plan%20for%20your%20spec...."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:e1000097. 10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186383","article-title":"Juvenile myasthenia gravis in Norway: HLA-DRB1*04:04 is positively associated with prepubertal onset","volume":"12","author":"Popperud TH","year":"2017","unstructured":"Popperud TH, Viken MK, Kerty E, Lie BA. Juvenile myasthenia gravis in Norway: HLA-DRB1*04:04 is positively associated with prepubertal onset. PLoS One. 2017, 12:e0186383. 10.1371\/journal.pone.0186383","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.04.002","article-title":"HLA and age of onset in myasthenia gravis","volume":"27","author":"Santos E","year":"2017","unstructured":"Santos E, Bettencourt A, da Silva AM, et al.. HLA and age of onset in myasthenia gravis. Neuromuscul Disord. 2017, 27:650-4. 10.1016\/j.nmd.2017.04.002","journal-title":"Neuromuscul Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2012.04.001","article-title":"Association of HLA-DR\/DQ polymorphism with myasthenia gravis in Tunisian patients","volume":"115","author":"Fekih-Mrissa N","year":"2013","unstructured":"Fekih-Mrissa N, Klai S, Zaouali J, Gritli N, Mrissa R. Association of HLA-DR\/DQ polymorphism with myasthenia gravis in Tunisian patients. Clin Neurol Neurosurg. 2013, 115:32-6. 10.1016\/j.clineuro.2012.04.001","journal-title":"Clin Neurol Neurosurg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036603","article-title":"Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population","volume":"7","author":"Maniaol AH","year":"2012","unstructured":"Maniaol AH, Elsais A, Lorentzen \u00c5R, et al.. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One. 2012, 7:e36603. 10.1371\/journal.pone.0036603","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2011.05.002","article-title":"Association between HLA-DRB1 and myasthenia gravis in a northern Han Chinese population","volume":"18","author":"Xie YC","year":"2011","unstructured":"Xie YC, Qu Y, Sun L, et al.. Association between HLA-DRB1 and myasthenia gravis in a northern Han Chinese population. J Clin Neurosci. 2011, 18:1524-7. 10.1016\/j.jocn.2011.05.002","journal-title":"J Clin Neurosci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2003.10.003","article-title":"HLA class II and class I polymorphism in Venezuelan patients with myasthenia gravis","volume":"65","author":"Fern\u00e1ndez-Mestre MT","year":"2004","unstructured":"Fern\u00e1ndez-Mestre MT, Vargas V, Montagnani S, Cot\u00faa M, Ogando V, Layrisse Z. HLA class II and class I polymorphism in Venezuelan patients with myasthenia gravis. Hum Immunol. 2004, 65:54-9. 10.1016\/j.humimm.2003.10.003","journal-title":"Hum Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2016.57.2.419","article-title":"The epidemiology of myasthenia gravis in Korea","volume":"57","author":"Lee HS","year":"2016","unstructured":"Lee HS, Lee HS, Shin HY, Choi YC, Kim SM. The epidemiology of myasthenia gravis in Korea. Yonsei Med J. 2016, 57:419-25. 10.3349\/ymj.2016.57.2.419","journal-title":"Yonsei Med J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000311012","article-title":"Nationwide population-based epidemiological study of myasthenia gravis in Taiwan","volume":"35","author":"Lai CH","year":"2010","unstructured":"Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in Taiwan. Neuroepidemiology. 2010, 35:66-71. 10.1159\/000311012","journal-title":"Neuroepidemiology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai H","year":"2011","unstructured":"Murai H, Yamashita N, Watanabe M, et al.. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci. 2011, 305:97-102. 10.1016\/j.jns.2011.03.004","journal-title":"J Neurol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2007.05.002","article-title":"Epidemiology of autoimmune diseases in Denmark","volume":"29","author":"Eaton WW","year":"2007","unstructured":"Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007, 29:1-9. 10.1016\/j.jaut.2007.05.002","journal-title":"J Autoimmun"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000026179","article-title":"Incidence and prevalence of myasthenia gravis in the county of the coast and Gorski kotar, Croatia, 1976 through 1996","volume":"17","author":"Zivadinov R","year":"1998","unstructured":"Zivadinov R, Jurjevic A, Willheim K, Cazzato G, Zorzon M. Incidence and prevalence of myasthenia gravis in the county of the coast and Gorski kotar, Croatia, 1976 through 1996. Neuroepidemiology. 1998, 17:265-72. 10.1159\/000026179","journal-title":"Neuroepidemiology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000342777","article-title":"Epidemiological study of adult-onset myasthenia gravis in the area of Belgrade (Serbia) in the period 1979-2008","volume":"40","author":"Lavrnic D","year":"2013","unstructured":"Lavrnic D, Basta I, Rakocevic-Stojanovic V, et al.. Epidemiological study of adult-onset myasthenia gravis in the area of Belgrade (Serbia) in the period 1979-2008. Neuroepidemiology. 2013, 40:190-4. 10.1159\/000342777","journal-title":"Neuroepidemiology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12233","article-title":"Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries","volume":"129","author":"Andersen JB","year":"2014","unstructured":"Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand Suppl. 2014, 129:26-31. 10.1111\/ane.12233","journal-title":"Acta Neurol Scand Suppl"},{"key":"ref26","article-title":"Myasthenia gravis in adults of institutions pertaining to the Mexican public health system: an analysis of hospital discharges during","volume":"151","author":"Tolosa-Tort P","year":"2015","unstructured":"Tolosa-Tort P, Chiquete E, Dominguez-Moreno R, et al.. Myasthenia gravis in adults of institutions pertaining to the Mexican public health system: an analysis of hospital discharges during. Gac Med Mex. 2015, 151:47-53.","journal-title":"Gac Med Mex"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12310","article-title":"The autoimmune spectrum of myasthenia gravis: a Swedish population-based study","volume":"277","author":"Fang F","year":"2015","unstructured":"Fang F, Sveinsson O, Thormar G, et al.. The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med. 2015, 277:594-604. 10.1111\/joim.12310","journal-title":"J Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-017-2840-1","article-title":"A first description of the Colombian national registry for rare diseases","volume":"10","author":"Mateus HE","year":"2017","unstructured":"Mateus HE, P\u00e9rez AM, Mesa ML, et al.. A first description of the Colombian national registry for rare diseases. BMC Res Notes. 2017, 10:514. 10.1186\/s13104-017-2840-1","journal-title":"BMC Res Notes"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-022-00516-3","article-title":"The relationship between myasthenia gravis and COVID-19: a systematic review","volume":"58","author":"Tugasworo D","year":"2022","unstructured":"Tugasworo D, Kurnianto A, Retnaningsih, Andhitara Y, Ardhini R, Budiman J. The relationship between myasthenia gravis and COVID-19: a systematic review. Egypt J Neurol Psychiatr Neurosurg. 2022, 58:83. 10.1186\/s41983-022-00516-3","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11472-6","article-title":"New-onset myasthenia gravis after SARS-CoV-2 infection: case report and literature review","volume":"270","author":"Tereshko Y","year":"2023","unstructured":"Tereshko Y, Gigli GL, Pez S, De Pellegrin A, Valente M. New-onset myasthenia gravis after SARS-CoV-2 infection: case report and literature review. J Neurol. 2023, 270:601-9. 10.1007\/s00415-022-11472-6","journal-title":"J Neurol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231191025","article-title":"Autoimmune myasthenia gravis and COVID-19. A case report-based review","volume":"51","author":"Croitoru CG","year":"2023","unstructured":"Croitoru CG, Cuciureanu DI, Hodorog DN, Grosu C, Cianga P. Autoimmune myasthenia gravis and COVID-19. A case report-based review. J Int Med Res. 2023, 51:3000605231191025. 10.1177\/03000605231191025","journal-title":"J Int Med Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/276926-correlation-between-the-prevalence-of-myasthenia-gravis-and-the-frequency-of-class-ii-human-leucocyte-antigen-alleles-in-various-geographical-locations-around-the-world","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T08:01:36Z","timestamp":1726819296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/276926-correlation-between-the-prevalence-of-myasthenia-gravis-and-the-frequency-of-class-ii-human-leucocyte-antigen-alleles-in-various-geographical-locations-around-the-world"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.69791","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,20]]}}}